AbCellera Biologics Inc. completed its initial public offering and its shares are now available on the Nasdaq under "ABCL." Vancouver-based AbCellera is an AI-powered drug discovery company working with Eli Lilly & Co. on a COVID-19 vaccine.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.52 |
|---|---|
| 52-week range | $2.34 - $6.06 |
| 50-day moving average | $2.64 |
| 200-day moving average | $3.88 |
| Wall St. target price | $15.43 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.53 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.52 from 2024-10-14
| 1 week (2024-10-08) | -1.95% |
|---|---|
| 1 month (2024-09-13) | -8.36% |
| 3 months (2024-07-15) | -21.25% |
| 6 months (2024-04-15) | -39.71% |
| 1 year (2023-10-13) | -40.85% |
|---|---|
| 2 years (2022-10-11) | N/A |
| 3 years (2021-10-15) | 15.53 |
| 5 years (2019-10-11) | N/A |
| Revenue TTM | $33.1 million |
|---|---|
| Gross profit TTM | $311.1 million |
| Return on assets TTM | -11.41% |
| Return on equity TTM | -13.3% |
| Profit margin | 0% |
| Book value | $3.77 |
| Market Capitalization | $757.3 million |
TTM: trailing 12 months
Over the last 12 months, AbCellera Biologics's shares have ranged in value from as little as $2.335 up to $6.055. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AbCellera Biologics's is 0.372. This would suggest that AbCellera Biologics's shares are less volatile than average (for this exchange).
To put AbCellera Biologics's beta into context you can compare it against those of similar companies.
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.